<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">
<pdf2xml producer="poppler" version="23.04.0">
<page number="1" position="absolute" top="0" left="0" height="792" width="612">
	<fontspec id="font0" size="11" family="Helvetica-Black,Bold" color="#ffffff"/>
	<fontspec id="font1" size="8" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font2" size="8" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font3" size="8" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font4" size="7" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font5" size="2" family="AkzidenzGroteskBE" color="#ffffff"/>
	<fontspec id="font6" size="15" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font7" size="16" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font8" size="12" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font9" size="6" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font10" size="8" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
	<fontspec id="font11" size="11" family="AkzidenzGroteskBE,Bold" color="#000000"/>
	<fontspec id="font12" size="9" family="AkzidenzGroteskBE-Md,Bold" color="#000000"/>
	<fontspec id="font13" size="9" family="AkzidenzGroteskBE" color="#000000"/>
	<fontspec id="font14" size="9" family="AkzidenzGroteskBE-It,Italic" color="#000000"/>
<text top="85" left="477" width="78" height="10" font="font0" id="p1_t1" reading_order_no="1" segment_no="1" tag_type="title">Open Access<a href="http://www.biomedcentral.com/info/about/charter/"><b>Open Access</b></a></text>
<text top="42" left="315" width="241" height="7" font="font1" id="p1_t2" reading_order_no="0" segment_no="0" tag_type="text">Available online http://breast-cancer-research.com/content/8/6/R66<b>Available online</b></text>
<text top="758" left="509" width="45" height="7" font="font3" id="p1_t3" reading_order_no="68" segment_no="30" tag_type="text">Page 1 of 12</text>
<text top="769" left="434" width="120" height="6" font="font4" id="p1_t4" reading_order_no="69" segment_no="31" tag_type="text">(page number not for citation purposes)</text>
<text top="85" left="57" width="9" height="2" font="font5" id="p1_t5" reading_order_no="2" segment_no="2" tag_type="title">Vol 8 No 6<i>(page number not for citation purposes)</i></text>
<text top="85" left="57" width="103" height="14" font="font6" id="p1_t6" reading_order_no="3" segment_no="2" tag_type="title">Research article</text>
<text top="102" left="57" width="462" height="14" font="font7" id="p1_t7" reading_order_no="4" segment_no="3" tag_type="title">Molecular subtypes of breast cancer in relation to paclitaxel</text>
<text top="120" left="57" width="456" height="14" font="font7" id="p1_t8" reading_order_no="5" segment_no="3" tag_type="title">response and outcomes in women with metastatic disease:<b>Molecular subtypes of breast cancer in relation to paclitaxel </b></text>
<text top="138" left="57" width="191" height="14" font="font7" id="p1_t9" reading_order_no="6" segment_no="3" tag_type="title">results from CALGB 9342<b>response and outcomes in women with metastatic disease: </b></text>
<text top="155" left="57" width="457" height="12" font="font8" id="p1_t10" reading_order_no="7" segment_no="4" tag_type="text">Lyndsay N Harris 1 , Gloria Broadwater 2 , Nancy U Lin 1 , Alexander Miron 1 , Stuart J Schnitt 3 ,<b>results from CALGB 9342</b></text>
<text top="171" left="57" width="480" height="12" font="font8" id="p1_t11" reading_order_no="8" segment_no="4" tag_type="text">David Cowan 4 , Jonathan Lara 5 , Ira Bleiweiss 6 , Donald Berry 7 , Matthew Ellis 8 , Daniel F Hayes 9 ,</text>
<text top="187" left="57" width="170" height="12" font="font8" id="p1_t12" reading_order_no="9" segment_no="4" tag_type="text">Eric P Winer 1 and Lynn Dressler 4</text>
<text top="221" left="57" width="292" height="7" font="font3" id="p1_t13" reading_order_no="10" segment_no="5" tag_type="text">1 Dana-Farber Cancer Institute, 44 Binney Street, Boston, Massachusetts 02115, USA</text>
<text top="230" left="57" width="304" height="8" font="font3" id="p1_t14" reading_order_no="11" segment_no="6" tag_type="text">2 Duke University Medical Center, 2301 Erwin Road, Durham, North Carolina 27710, USA</text>
<text top="240" left="57" width="343" height="7" font="font3" id="p1_t15" reading_order_no="12" segment_no="7" tag_type="text">3 Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, Massachusetts 02215, USA</text>
<text top="249" left="57" width="323" height="8" font="font3" id="p1_t16" reading_order_no="13" segment_no="8" tag_type="text">4 University of North Carolina, 250 East Franklin Street, Chapel Hill, North Carolina 27514, USA</text>
<text top="259" left="57" width="314" height="7" font="font3" id="p1_t17" reading_order_no="14" segment_no="9" tag_type="text">5 St. Barnabas Medical Center, 94 Old Short Hills Road, Livingston, New Jersey 07039, USA</text>
<text top="268" left="57" width="328" height="8" font="font3" id="p1_t18" reading_order_no="15" segment_no="10" tag_type="text">6 Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, New York 10029, USA</text>
<text top="278" left="57" width="299" height="7" font="font3" id="p1_t19" reading_order_no="16" segment_no="11" tag_type="text">7 MD Anderson Cancer Center, 1515 Holcolmb Boulevard, Houston, Texas 77030, USA</text>
<text top="287" left="57" width="323" height="8" font="font3" id="p1_t20" reading_order_no="17" segment_no="12" tag_type="text">8 Washington University Medical Center, 660 S. Euclid Avenue, St. Louis, Missouri 63110, USA</text>
<text top="297" left="57" width="410" height="7" font="font3" id="p1_t21" reading_order_no="18" segment_no="13" tag_type="text">9 University of Michigan Comprehensive Cancer Center, 1500 E. Medical Center Drive, Ann Arbor, Michigan 48109, USA</text>
<text top="315" left="57" width="222" height="7" font="font3" id="p1_t22" reading_order_no="19" segment_no="14" tag_type="text">Corresponding author: Lyndsay N Harris, lyndsay.harris@yale.edu</text>
<text top="333" left="57" width="492" height="7" font="font3" id="p1_t23" reading_order_no="20" segment_no="15" tag_type="text">Received: 14 Jun 2006 Revisions requested: 4 Aug 2006 Revisions received: 24 Oct 2006 Accepted: 27 Nov 2006 Published: 27 Nov 2006</text>
<text top="352" left="57" width="213" height="7" font="font10" id="p1_t24" reading_order_no="21" segment_no="16" tag_type="text">Breast Cancer Research 2006, 8 :R66 (doi:10.1186/bcr1622)</text>
<text top="362" left="57" width="256" height="7" font="font3" id="p1_t25" reading_order_no="22" segment_no="17" tag_type="text">This article is online at: http://breast-cancer-research.com/content/8/6/R66</text>
<text top="372" left="57" width="174" height="7" font="font3" id="p1_t26" reading_order_no="23" segment_no="18" tag_type="text">Â© 2006 Harris et al .; licensee BioMed Central Ltd.</text>
<text top="382" left="57" width="500" height="7" font="font3" id="p1_t27" reading_order_no="24" segment_no="19" tag_type="text">This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0),</text>
<text top="392" left="57" width="409" height="7" font="font3" id="p1_t28" reading_order_no="25" segment_no="19" tag_type="text">which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</text>
<text top="421" left="57" width="43" height="10" font="font11" id="p1_t29" reading_order_no="26" segment_no="20" tag_type="title">Abstract</text>
<text top="442" left="57" width="240" height="8" font="font12" id="p1_t30" reading_order_no="27" segment_no="21" tag_type="text">Introduction The response to paclitaxel varies widely in</text>
<text top="452" left="57" width="240" height="8" font="font13" id="p1_t31" reading_order_no="28" segment_no="21" tag_type="text">metastatic breast cancer. We analyzed data from CALGB 9342,</text>
<text top="463" left="57" width="240" height="8" font="font13" id="p1_t32" reading_order_no="29" segment_no="21" tag_type="text">which tested three doses of paclitaxel in women with advanced</text>
<text top="473" left="57" width="240" height="8" font="font13" id="p1_t33" reading_order_no="30" segment_no="21" tag_type="text">disease, to determine whether response and outcomes differed</text>
<text top="484" left="57" width="211" height="8" font="font13" id="p1_t34" reading_order_no="31" segment_no="21" tag_type="text">according to HER2, hormone receptor, and p53 status.</text>
<text top="505" left="57" width="240" height="8" font="font12" id="p1_t35" reading_order_no="32" segment_no="23" tag_type="text">Methods Among 474 women randomly assigned to paclitaxel at</text>
<text top="515" left="57" width="240" height="8" font="font13" id="p1_t36" reading_order_no="33" segment_no="23" tag_type="text">a dose of 175, 210, or 250 mg/m 2 , adequate primary tumor</text>
<text top="526" left="57" width="240" height="8" font="font13" id="p1_t37" reading_order_no="34" segment_no="23" tag_type="text">tissue was available from 175. Immunohistochemistry with two</text>
<text top="536" left="57" width="241" height="8" font="font13" id="p1_t38" reading_order_no="35" segment_no="23" tag_type="text">antibodies and fluorescence in situ hybridization were</text>
<text top="547" left="57" width="240" height="8" font="font13" id="p1_t39" reading_order_no="36" segment_no="23" tag_type="text">performed to evaluate HER2 status; p53 status was determined</text>
<text top="557" left="57" width="241" height="8" font="font13" id="p1_t40" reading_order_no="37" segment_no="23" tag_type="text">by immunohistochemistry and sequencing. Hormone receptor</text>
<text top="568" left="57" width="168" height="8" font="font13" id="p1_t41" reading_order_no="38" segment_no="23" tag_type="text">status was obtained from pathology reports.</text>
<text top="589" left="57" width="240" height="8" font="font12" id="p1_t42" reading_order_no="39" segment_no="25" tag_type="text">Results Objective response rate was not associated with HER2</text>
<text top="599" left="57" width="240" height="8" font="font13" id="p1_t43" reading_order_no="40" segment_no="25" tag_type="text">or p53 status. There was a trend toward a shorter median time</text>
<text top="610" left="57" width="240" height="8" font="font13" id="p1_t44" reading_order_no="41" segment_no="25" tag_type="text">to treatment failure among women with HER2-positive tumors</text>
<text top="442" left="315" width="240" height="8" font="font13" id="p1_t45" reading_order_no="42" segment_no="22" tag_type="text">(2.3 versus 4.2 months; P = 0.067). HER2 status was not</text>
<text top="452" left="315" width="240" height="8" font="font13" id="p1_t46" reading_order_no="43" segment_no="22" tag_type="text">related to overall survival (OS). Hormone receptor expression</text>
<text top="463" left="315" width="240" height="8" font="font13" id="p1_t47" reading_order_no="44" segment_no="22" tag_type="text">was not associated with differences in response but was</text>
<text top="473" left="315" width="240" height="8" font="font13" id="p1_t48" reading_order_no="45" segment_no="22" tag_type="text">associated with longer OS ( P = 0.003). In contrast, women with</text>
<text top="484" left="315" width="241" height="8" font="font13" id="p1_t49" reading_order_no="46" segment_no="22" tag_type="text">p53 over-expression had significantly shorter OS than those</text>
<text top="494" left="315" width="241" height="8" font="font13" id="p1_t50" reading_order_no="47" segment_no="22" tag_type="text">without p53 over-expression (11.5 versus 14.4 months; P =</text>
<text top="505" left="315" width="240" height="8" font="font13" id="p1_t51" reading_order_no="48" segment_no="22" tag_type="text">0.002). In addition, triple negative tumors were more frequent in</text>
<text top="515" left="315" width="240" height="8" font="font13" id="p1_t52" reading_order_no="49" segment_no="22" tag_type="text">African-American than in Caucasian patients, and were</text>
<text top="526" left="315" width="240" height="8" font="font13" id="p1_t53" reading_order_no="50" segment_no="22" tag_type="text">associated with a significant reduction in OS (8.7 versus 12.9</text>
<text top="536" left="315" width="78" height="8" font="font13" id="p1_t54" reading_order_no="51" segment_no="22" tag_type="text">months; P = 0.008).</text>
<text top="568" left="315" width="241" height="8" font="font12" id="p1_t55" reading_order_no="52" segment_no="24" tag_type="text">Conclusion None of the biomarkers was predictive of treatment</text>
<text top="578" left="315" width="241" height="8" font="font13" id="p1_t56" reading_order_no="53" segment_no="24" tag_type="text">response in women with metastatic breast cancer; however,</text>
<text top="589" left="315" width="240" height="8" font="font13" id="p1_t57" reading_order_no="54" segment_no="24" tag_type="text">survival differed according to hormone receptor and p53 status.</text>
<text top="599" left="315" width="240" height="8" font="font13" id="p1_t58" reading_order_no="55" segment_no="24" tag_type="text">Triple negative tumors were more frequent in African-American</text>
<text top="610" left="315" width="199" height="8" font="font13" id="p1_t59" reading_order_no="56" segment_no="24" tag_type="text">patients and were associated with a shorter survival.<i>Breast Cancer Research</i></text>
<text top="659" left="57" width="64" height="10" font="font11" id="p1_t60" reading_order_no="57" segment_no="26" tag_type="title">Introduction</text>
<text top="671" left="57" width="240" height="9" font="font13" id="p1_t61" reading_order_no="58" segment_no="28" tag_type="text">The taxanes (paclitaxel and docetaxel) are among the most<b>8</b></text>
<text top="683" left="57" width="240" height="9" font="font13" id="p1_t62" reading_order_no="59" segment_no="28" tag_type="text">active drugs for treatment of breast cancer and are an impor-</text>
<text top="694" left="57" width="240" height="9" font="font13" id="p1_t63" reading_order_no="60" segment_no="28" tag_type="text">tant component of treatment in the neoadjuvant, adjuvant, and<a href="http://breast-cancer-research.com/content/8/6/R66">This article is online at: http://breast-cancer-research.com/content/8/6/R66</a></text>
<text top="659" left="315" width="240" height="9" font="font13" id="p1_t64" reading_order_no="61" segment_no="27" tag_type="text">metastatic settings. These drugs act, at least in part, by stabi-</text>
<text top="671" left="315" width="241" height="10" font="font13" id="p1_t65" reading_order_no="62" segment_no="27" tag_type="text">lizing microtubules and inducing G 2 /M arrest, with subsequent<i> et al</i></text>
<text top="683" left="315" width="240" height="9" font="font13" id="p1_t66" reading_order_no="63" segment_no="27" tag_type="text">apoptosis in malignant cells. Paclitaxel, the first taxane that</text>
<text top="694" left="315" width="240" height="9" font="font13" id="p1_t67" reading_order_no="64" segment_no="27" tag_type="text">was developed, has substantial antitumor activity. As a result,<a href="http://creativecommons.org/licenses/by/2.0"> (http://creativecommons.org/licenses/by/2.0), </a></text>
<text top="714" left="57" width="498" height="7" font="font3" id="p1_t68" reading_order_no="65" segment_no="29" tag_type="footnote">CALGB â Cancer and Leukemia Group B; CI = confidence interval; ER = estrogen receptor; FISH = fluorescent in situ hybridization; HER = human</text>
<text top="724" left="57" width="497" height="7" font="font3" id="p1_t69" reading_order_no="66" segment_no="29" tag_type="footnote">epidermal growth factor receptor; IHC = immunohistochemistry; NSABP = National Surgical Adjuvant Breast and Bowel Project; OS = overall sur-<b>Abstract</b></text>
<text top="733" left="57" width="224" height="7" font="font3" id="p1_t70" reading_order_no="67" segment_no="29" tag_type="footnote">vival; PR = progesterone receptor; TTF = time to treatment failure.<b>Introduction</b></text>
</page>
</pdf2xml>
